Evaluation of the response of lisdexamfetamine in children and adolescents with ADHD: quasi-experimental study.
Introduction. Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. Although lisdexamfetamine dimesylate (LDX) offers a treatment alternative, clinical evidence of LDX for ADHD has not been explored in Latin American pediatric population. Objective....
| Publicado en: | Salud Mental Vol. 41; no. 6; pp. 279 - 286 |
|---|---|
| Autores principales: | , , |
| Formato: | Artículo |
| Publicado: |
Instituto Nacional de Psiquiatria Ramon de la Fuente
Nov/Dec2018
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=133743826&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 133743826 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 01853325 7LB jtl: Salud Mental issn: 01853325 maglogo: N pubinfo: dt: Nov/Dec2018 vid: 41 iid: 6 pid: 20856 pub: Instituto Nacional de Psiquiatria Ramon de la Fuente artinfo: ui: 133743826 10.17711/SM.0185-3325.2018.040 ppf: 279 ppct: 7 formats: fmt: @attributes: type: P size: 1.2MB tig: atl: Evaluation of the response of lisdexamfetamine in children and adolescents with ADHD: quasi-experimental study. aug: au: Pérez Eduardo, Barragán Juan Carlos, García Beristain Gutiérrez Ricardo, Hidalgo affil: Departamento de Neurología, Hospital Infantil de México Federico Gómez, Ciudad de México, México su: Attention-deficit hyperactivity disorder Children with attention-deficit hyperactivity disorder Youth with attention-deficit hyperactivity disorder Movement disorders Amphetamines Treatment of attention-deficit hyperactivity disorder sug: subj: Attention-deficit hyperactivity disorder Children with attention-deficit hyperactivity disorder Youth with attention-deficit hyperactivity disorder Movement disorders Amphetamines Treatment of attention-deficit hyperactivity disorder keyword: ADHD attention deficit lisdexamfetamine dimesylate motor hyperactivity déficit de atención dimesilato de lisdexanfetamina hiperactividad motora TDAH ab: Introduction. Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. Although lisdexamfetamine dimesylate (LDX) offers a treatment alternative, clinical evidence of LDX for ADHD has not been explored in Latin American pediatric population. Objective. To evaluate the LDX response in Mexican pediatric patients with ADHD. Method. We designed a quasi-experimental, uncontrolled before and after study to evaluate the LDX response in patients with severe ADHD. We established a diagnosis of ADHD according to DSM-5 criteria. We formed three groups: without previous treatment (group A), in treatment with stimulant drugs (group B) or in treatment with non-stimulant drugs (group C). Prior to the start of the study, letters of consent and informed consent were signed. We evaluated the effect of LDX based on the difference between ADHD-RS scores at the beginning and after six months. Results. We recruited a total of 144 patients (group A: 48 patients, group B: 57 patients, group C: 39 patients). All the groups showed a significant decrease in the mean score of ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) at six months (group A 37.57 vs. 22.34, p <.01), (group B 36.72 vs. 24.45; p <. 01), (group C 38.54 vs. 24.3, p <.01). Fewer than 30% of the subjects showed a significant adverse reaction, the most frequent ones being: sleep disturbance (primary insomnia) 24% and decreased appetite in 20%. Discussion and conclusion. Treatment with LDX is an effective, well-tolerated pharmacological option for Mexican pediatric patients with ADHD. Introducción. El trastorno por déficit de atención con hiperactividad (TDAH) es uno de los trastornos del neurodesarrollo más comunes. Aunque el dimesilato de lisdexanfetamina (LDX) ofrece una alternativa de tratamiento, la evidencia clínica de LDX para TDAH no se ha explorado en población pediátrica latinoamericana. Objetivo. Evaluar la respuesta de LDX en pacientes pediátricos mexicanos con TDAH. Método. Diseñamos un estudio cuasiexperimental no controlado de antes y después para evaluar la respuesta de LDX en pacientes con TDAH grave. Establecimos el diagnóstico de TDAH de acuerdo con criterios del DSM-5. Conformamos tres grupos: sin tratamiento previo (grupo A), en tratamiento con fármacos estimulantes (grupo B) o en tratamiento con fármacos no estimulantes (grupo C). Previo al inicio del estudio se firmaron las cartas de consentimiento y asentimiento informado. Evaluamos el efecto de LDX con base en la diferencia de los puntajes de ADHD-RS al inicio y posterior a seis meses. Resultados. Reclutamos un total de 144 pacientes (grupo A: 48 pacientes, grupo B: 57 pacientes, grupo C: 39 pacientes). Todos los grupos mostraron una disminución significativa en la media de puntaje de ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) a los seis meses (grupo A 37.57 vs. 22.34; p < .01), (grupo B 36.72 vs. 24.45; p < .01), (grupo C 38.54 vs. 24.3; p < .01). Menos del 30% de los sujetos presentó alguna reacción adversa importante, siendo las más frecuentes: alteraciones del sueño (insomnio primario) 24% y disminución del apetito en 20%. Discusión y conclusión. El tratamiento con LDX es una opción farmacológica efectiva y bien tolerada para pacientes pediátricos mexicanos con TDAH. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Copyright of Salud Mental is the property of Instituto Nacional de Psiquiatria Ramon de la Fuente and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: Salud Mental holder: Instituto Nacional de Psiquiatria Ramon de la Fuente dt: @attributes: year: 2018 holdings: @attributes: islocal: N |
|---|